Salubris Biotherapeutics, Inc., (hereinafter referred to as "SalubrisBio"), as a wholly owned subsidiary of Shenzhen Salubris Pharmaceuticals Co. Ltd., submitted a clinical application for SAL007 to FDA on January 23, 2020, and was successfully appro
On December 25, 2019, Salubris formally signed an agreement with Japan's JAPAN TOBACCO INC. (hereinafter referred to as "JT") at its headquarters in Shenzhen
Recently, Genemen Biotech (Suzhou) Co., Ltd., a subsidiary of Shenzhen Salubris Pharmaceuticals Co., Ltd., received the Drug Registration Approval Document of "Recombinant Teriparatide for Injection" (Xinfutai) approved and issued by National Medical
Recently, Salubris's Pitavastatin Calcium Tablets 2mg (trademark: Xinliming) was approved for market launch. So far, Salubris have involved in lipid-lowering, antihypertensive and antithrombotic filed, further strengthening its dominant position in t
Exciting! Recently, Taiyi (Ticagrelor), a super product in cardiovascular field of Salubris Pharmaceuticals, was approved for marketing, winning the first place and taking the lead in the market.
On June 8th, the signing ceremony of Salubris's investment and M&A with Suzhou Huanchen Medical Technology Co., Ltd. was held at Salubris Group Headquarters. Salubris will obtain 100% stock right of Suzhou Huanchen in stages with its own capital of R
